Lin MH, et al. Real-world brigatinib use in non-small cell lung cancer patients with prior use of crizotinib/other ALK therapies in the US. Abstract P2.16-09. WCLC 2019, 7-10 sept. Barcelona, Spanje.
ERBB-mutaties als biomarker voor uitkomst plaveiselcelcarcinoom van de long?
jan 2019 | Longoncologie